GSK-2881078 is a non-steroidal selective androgen receptor modulator (SARM) originally developed by GlaxoSmithKline. In well-designed Phase 1 and Phase 2 clinical trials, it produced clear, dose-dependent increases in lean body mass in both healthy older men and postmenopausal women, with additional signals of improved leg strength in men when combined with exercise. It was generally well tolerated, with manageable and reversible effects on lipids (mainly HDL reduction) and occasional transient elevations in liver enzymes.
What sets GSK-2881078 apart is not just the data it generated, but the process behind that data. It went through proper first-in-human studies, dose-ranging work, and a dedicated Phase 2a trial in a relevant patient population (older adults with COPD and muscle weakness), all with published results in peer-reviewed journals. Development was ultimately discontinued by GSK for strategic and portfolio reasons — not because of hidden safety disasters or efficacy failures that were later revealed.
In a field crowded with research chemicals, vendor hype, and compounds that skipped rigorous clinical vetting, GSK-2881078 stands as a concrete example of what responsible, high-quality selective modulator development looks like. This ELEVATE Guide examines its chemistry, mechanism of tissue selectivity, every published clinical study with actual numbers and design details, comparisons to other SARMs, safety profile, why major pharmaceutical development matters, and what the broader selective modulator space can learn from it.
All content is strictly for educational and research purposes. GSK-2881078 is not approved by the FDA or most major regulatory agencies and remains a research compound.
Introduction
Selective androgen receptor modulators were created with a specific promise: deliver the muscle- and bone-building benefits of androgens while minimizing unwanted effects on the prostate, skin, hair, and cardiovascular system. The idea is elegant in theory — design molecules that change the shape of the androgen receptor just enough to recruit different sets of coactivators and corepressors in different tissues.
In practice, the SARM landscape has been messy. Many compounds popular in research chemical circles have thin or nonexistent published human data. Some showed concerning signals in early work that were downplayed. Others were rushed to market with more marketing than medicine behind them.
GSK-2881078 is different. It came from a major pharmaceutical company with the resources and regulatory standards to run proper clinical trials. The data that exist were generated under Good Clinical Practice conditions, published transparently, and include both efficacy signals and the side effects that appeared. When GSK decided the program no longer fit their portfolio, they stopped development openly rather than quietly burying problems.
This makes GSK-2881078 a useful benchmark. It shows what is realistically achievable with current SARM technology when you actually do the work: meaningful lean mass gains, functional signals in relevant populations, and a tolerability profile that, while not perfect, is documented and manageable within the context of short-to-medium term studies.
This guide will go deep into the science and the data so you can see exactly why this compound earned its reputation as one of the cleaner, more rigorously studied examples in the category — and what that means for how selective modulators should be evaluated going forward.
Literature Review
The Androgen Receptor and the Goal of Selectivity
The androgen receptor (AR) is a nuclear receptor. When testosterone or dihydrotestosterone binds, the receptor changes shape, moves into the nucleus, binds DNA at androgen response elements, and recruits coactivator proteins that turn on gene transcription. Different tissues have different mixes of coactivators and corepressors, and the exact shape the receptor takes when a ligand binds influences which ones it prefers.
Traditional anabolic-androgenic steroids are not selective. They activate the receptor strongly everywhere, which is why you get both the desired muscle effects and the unwanted prostate growth, acne, hair loss, and suppression of natural testosterone production.
SARMs are designed to be “partial” or “tissue-selective” agonists. The ideal profile is:
- Strong agonist activity in skeletal muscle and bone (anabolic).
- Minimal or antagonist activity in prostate and seminal vesicles.
- Limited impact on skin, hair follicles, and sebaceous glands.
- Manageable effects on the hypothalamic-pituitary-gonadal axis and lipids.
GSK-2881078 was engineered as a non-steroidal small molecule that achieves this profile through a specific binding mode that favors muscle and bone coactivator recruitment while limiting prostate effects.
Chemistry and Preclinical Profile
GSK-2881078 is a pyrrolidine-based or related non-steroidal scaffold (specific structure details are in the published patents and papers). It binds the ligand-binding domain of the AR with high affinity and shows tissue-selective gene regulation in cell-based assays and animal models.
In preclinical work, it increased muscle mass and bone mineral density in rodent models while having significantly less effect on prostate weight compared with testosterone or other androgens. It was orally bioavailable, which is a practical advantage for clinical development.
Importantly, GSK published early mechanistic and safety data alongside the later human trials, which is more transparency than is typical for many research chemicals that never had formal development programs.
Phase 1 Clinical Data – First-in-Human and Dose-Ranging
The foundational human data come from studies led by Clark et al. (published 2017–2018).
In the first-in-human study, healthy volunteers received single and multiple doses. GSK-2881078 was well tolerated across the dose range tested. Pharmacodynamic effects included the expected reductions in sex hormone-binding globulin (SHBG) and high-density lipoprotein (HDL) cholesterol — classic androgenic effects on lipids and binding proteins. No serious adverse events were attributed to the drug in these early cohorts.
A subsequent Phase 1b study explored a range of doses in healthy older men and postmenopausal women for up to 28 days (with some longer cohorts). Key findings:
- Dose-dependent increases in lean body mass (measured by DXA).
- Women showed greater lean mass response at lower doses than men — an interesting sex difference that appeared consistently.
- Increases in thigh muscle volume were confirmed by MRI in some cohorts.
- The compound remained generally well tolerated.
- Transient, reversible elevations in alanine aminotransferase (ALT) were observed in some participants.
- No major safety signals emerged that would halt development.
These early studies established proof-of-concept for anabolic activity in humans and gave GSK the confidence to move into a dedicated patient population.
Phase 2a Trial in COPD Patients with Muscle Weakness
The most informative study is the Phase 2a trial in older men and postmenopausal women with chronic obstructive pulmonary disease (COPD) and muscle weakness. Participants received GSK-2881078 or placebo once daily for 13 weeks while also following a home-based exercise program.
Primary and key secondary outcomes included:
- Changes in lean body mass (total and appendicular).
- Leg strength (1-repetition maximum or similar measures).
- Functional measures such as walking capacity.
- Safety and tolerability, including lipids, liver enzymes, and hormone parameters.
Results (published in Thorax and related papers):
- GSK-2881078 produced statistically significant increases in total and appendicular lean body mass compared with placebo. The adjusted mean treatment difference was approximately 2.1 kg in both men and women.
- Leg strength improved. When expressed as percentage of predicted normal, the improvement reached statistical significance in men (roughly 7% greater improvement than placebo/exercise alone). The absolute force increase was numerically larger in men as well.
- Women showed robust lean mass gains but the strength signal was less clear or did not reach the same statistical threshold in that cohort.
- No major changes in patient-reported outcomes were detected in the relatively short 13-week window.
- Safety: The drug was generally well tolerated. The main treatment-related findings were reversible reductions in HDL cholesterol and transient elevations in hepatic transaminases in some participants. These were monitored and largely resolved after treatment ended. No serious safety issues unique to the compound emerged that would be considered deal-breakers for further development in the studied population.
This trial is notable because it combined the SARM with exercise (a realistic real-world scenario) and targeted a population that actually has muscle wasting and functional limitation — not just healthy volunteers.
Why Development Was Discontinued
In approximately 2020, GSK made a public strategic decision to stop further development of GSK-2881078. The company stated that the data did not support progression specifically for the COPD indication they were exploring. There was no announcement of new safety signals or efficacy failures that contradicted the published Phase 2 results. Portfolio prioritization and commercial considerations appear to have been the driving factors.
This transparency matters. Many compounds in the broader SARM space disappear from discussion without any public explanation. GSK’s approach — running proper trials, publishing the data, and then openly stating the business reason for stopping — is closer to how pharmaceutical development is supposed to work.
Methodology/Data Analysis
The quality of evidence for GSK-2881078 is higher than for most SARMs available as research chemicals because it followed a conventional clinical development path.
Study designs included randomized, double-blind, placebo-controlled elements. Doses were explored systematically. Endpoints were clinically relevant (lean mass by DXA, strength testing, functional measures). Safety monitoring included standard laboratory panels, lipids, hormones, and adverse event collection under GCP standards.
Limitations worth noting:
- The Phase 2 trial was relatively short (13 weeks). Longer-term data on sustained efficacy, bone outcomes, or cardiovascular risk markers beyond lipids are not available from large trials.
- The COPD population has its own comorbidities, so generalizing to healthy aging or other cachectic states requires caution.
- Strength improvements were more convincing in men than women in the published analysis; the reasons (dosing, baseline differences, statistical power) are not fully resolved in the available data.
- Like other SARMs, it produces HDL reduction. Whether this translates to actual cardiovascular risk increase is unknown without longer outcome studies.
- No large Phase 3 trials with hard clinical endpoints (falls, fractures, mortality, hospitalization) were completed.
Despite these gaps, the existing dataset is still one of the most complete and transparent for any SARM that reached mid-stage clinical testing.
Discussion
GSK-2881078 illustrates several important principles that selective modulator development should follow:
1. Rigorous, published clinical data beats vendor claims.
The lean mass increases seen with GSK-2881078 were measured with DXA and confirmed in some cases with MRI. They were dose-dependent and occurred in both healthy volunteers and a relevant patient population. This is different from compounds where the only “data” are before-and-after photos or small, poorly controlled user reports.
2. Tissue selectivity is real but not perfect.
GSK-2881078 showed the desired profile of stronger effects in muscle than in prostate-related tissues in preclinical models, and the human safety data did not show major virilizing effects in women or prostate issues in men at the doses and durations studied. However, it still produced classic androgenic effects on lipids (HDL lowering) and SHBG. True “side-effect-free” anabolism remains elusive; the goal is acceptable trade-offs that are well characterized.
3. Major pharma development brings accountability and transparency.
When a company like GSK runs trials, stops development, and publishes the results, the field gets usable information even if the drug never reaches market. This is vastly preferable to compounds that are never properly studied and then sold indefinitely with marketing that outpaces the evidence.
4. Functional outcomes matter more than scale weight or DEXA alone.
The COPD trial attempted to link lean mass gains to actual strength and function. While the strength signal was clearer in men, the attempt itself is the right direction. Future selective modulators should prioritize clinically meaningful endpoints (strength, physical function, quality of life, hard outcomes) rather than just body composition numbers.
5. Sex differences in response deserve attention.
Women in the GSK-2881078 studies often showed robust lean mass gains at lower doses than men. This has implications for dosing strategies and suggests that “one size fits all” approaches may not be optimal. Good development programs investigate and report these differences.
6. The HDL and liver enzyme signals are class effects that need management.
Almost all SARMs that have reached human testing lower HDL to some degree. Transient transaminase elevations also appear across several compounds. These are not reasons to dismiss the class, but they are reasons to demand proper monitoring and longer-term safety data before widespread use.
GSK-2881078 is not perfect, and it was never going to be a miracle drug. What it represents is a higher standard: published, peer-reviewed human data generated under regulatory-grade conditions, honest reporting of both benefits and side effects, and a clear decision-making process when development ended.
In a space where many selective modulators are discussed as if they are fully validated tools, GSK-2881078 reminds us what actual validation looks like — and how much work remains for the rest of the field.
Conclusion
GSK-2881078 is one of the best-documented selective androgen receptor modulators to reach mid-stage clinical development. It produced dose-dependent lean mass increases in older adults, showed functional strength signals in men with muscle weakness when combined with exercise, and maintained a generally acceptable tolerability profile in the studies conducted. Development was discontinued for business reasons after transparent publication of the data, not because of undisclosed safety catastrophes.
For researchers, clinicians, and anyone seriously interested in selective modulators, GSK-2881078 serves as a reference point. It demonstrates both what is achievable with current non-steroidal SARM technology and what responsible development requires: proper trials, published results, clear communication of limitations, and realistic expectations.
The broader lesson is that selectivity is not just a marketing claim — it is something that must be proven through rigorous, tissue-specific data in humans. Compounds that skip these steps, no matter how promising they look on paper or in anecdotes, fall short of the standard GSK-2881078 set during its development program.
Future selective modulators (whether androgen, estrogen, or other nuclear receptor targets) would do well to follow the same path of transparent, high-quality clinical research rather than hoping that mechanism alone is enough.
References
[1] Clark RV et al. Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator GSK2881078 in healthy men and postmenopausal women. Br J Clin Pharmacol. 2017.
[2] Neil D et al. GSK2881078, a SARM, produces dose-dependent increases in lean mass in healthy older men and women. J Cachexia Sarcopenia Muscle. 2018.
[3] Mohan D et al. Selective androgen receptor modulation for muscle weakness in COPD (Phase 2a results). Thorax. 2023.
[4] Additional GSK trial registry data and supporting mechanistic literature on non-steroidal SARMs.
FTC Disclosure: ELEVATE and ELEVATE Performance Marketing LLC maintain affiliate, referral, and marketing relationships with select research and wellness industry partners. We may receive compensation from purchases made through our links, discount codes, referrals, or other promotional partnerships.
Content shared by ELEVATE is intended solely for educational and informational purposes and should not be construed as medical advice. All statements, opinions, and recommendations expressed are our own.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Visit kimerachems.co and use code ELEVATE for 10% off your order of research compounds and peptides.
#GSK2881078 #SARM #SelectiveAndrogenReceptorModulator #LeanMass #MuscleResearch #COPDCachexia #ClinicalData #ResearchUseOnly #BiohackingScience #ELEVATEBiohacking #EvidenceBasedOptimization #LongevityResearch #NuclearReceptorModulators
Leave a Reply